Levetiracetam

American Journal of Health-System Pharmacy

Volumn 58, Issue 13, 2001, Pages 1195-1199

  Nash, E M ^a   Sangha, K S ^a   Kay, L ^a  

^a University HealthSystem Consortium   (United States)

Author keywords

Anticonvulsants; Dosage; Drug interactions; Epilepsy; Levetiracetam; Mechanism of action; Pharmacokinetics; Toxicity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIGOXIN; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PROBENECID; PUREPAC; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; WARFARIN; ZONEGRAM; ZONISAMIDE;

ASTHENIA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; FOCAL EPILEPSY; HUMAN; INFECTION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO;

EID: 0035395511     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.13.1195     Document Type: Review

References (13)

1. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
2. Progress report on new antiepileptic drugs: A summary of the Fourth Eilat Conference (EILAT IV)
3. Levetiracetam - A new therapeutic option for epilepsy
4. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
5. Special considerations for women with epilepsy
6. Complex partial seizures in adults